OBJECTIVES: To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. METHOD: In 115 seropositive arthralgia patients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. RESULTS: In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5-13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFN(high) individuals converted to arthritis, compared with 29 out of 90 IFN(low) individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFN(high) at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). CONCLUSIONS: The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.
OBJECTIVES: To validate the presence and demonstrate the clinical value of the type I interferon (IFN)-signature during arthritis development. METHOD: In 115 seropositive arthralgiapatients who were followed for the development of arthritis (Amsterdam Reade cohort), and 25 presymptomatic individuals who developed rheumatoid arthritis (RA) later, and 45 population-based controls (Northern Sweden cohort), the expression levels of 7 type I IFN response genes were determined with multiplex qPCR and an IFN-score was calculated. The diagnostic performance of the IFN-score was evaluated using Cox regression and Receiver Operating Characteristics (ROC)-curve analysis. RESULTS: In 44 of the 115 at-risk individuals (38%) from the Amsterdam Reade cohort, arthritis developed after a median period of 8 months (IQR 5-13). Stratification of these individuals based on the IFN-score revealed that 15 out of 25 IFN(high) individuals converted to arthritis, compared with 29 out of 90 IFN(low) individuals (p=0.011). In the Northern Sweden cohort, the level of the IFN-score was also significantly increased in presymptomatic individuals who developed RA compared with population-based controls (p=0.002). Cox regression analysis of the Amsterdam Reade cohort showed that the hazard ratio (HR) for development of arthritis was 2.38 (p=0.008) for IFN(high) at-risk individuals after correction for anticitrullinated protein antibodies (ACPA) and rheumatoid factor (RF). The ROC-curve area under the curve (AUC) for the IFN-score combined with ACPA and RF in the prediction of arthritis was 78.5% (p=0.0001, 95% CI 0.70 to 0.87). CONCLUSIONS: The results demonstrated clinical utility for the IFN-signature as a biomarker in the prediction of arthritis development.
Authors: Federica Vecchio; Nicola Lo Buono; Angela Stabilini; Laura Nigi; Matthew J Dufort; Susan Geyer; Paola Maria Rancoita; Federica Cugnata; Alessandra Mandelli; Andrea Valle; Pia Leete; Francesca Mancarella; Peter S Linsley; Lars Krogvold; Kevan C Herold; Helena Elding Larsson; Sarah J Richardson; Noel G Morgan; Knut Dahl-Jørgensen; Guido Sebastiani; Francesco Dotta; Emanuele Bosi; Manuela Battaglia Journal: JCI Insight Date: 2018-09-20
Authors: Tessa S van Kempen; Mark H Wenink; Emmerik F A Leijten; Timothy R D J Radstake; Marianne Boes Journal: Nat Rev Rheumatol Date: 2015-05-12 Impact factor: 20.543
Authors: Maxwell J Heinrich; Caroline A Purcell; Andrea J Pruijssers; Yang Zhao; Charles F Spurlock; Subramaniam Sriram; Kristen M Ogden; Terence S Dermody; Matthew B Scholz; Philip S Crooke; John Karijolich; Thomas M Aune Journal: J Autoimmun Date: 2019-02-28 Impact factor: 7.094
Authors: Elizabeth W Karlson; Dirkjan van Schaardenburg; Annette H van der Helm-van Mil Journal: Rheumatology (Oxford) Date: 2014-08-04 Impact factor: 7.580
Authors: John T Tossberg; Rachel M Heinrich; Virginia M Farley; Philip S Crooke; Thomas M Aune Journal: J Immunol Date: 2020-10-12 Impact factor: 5.422